International Journal of Natural Medicine and Health Sciences
ISSN (Online):2790-2471 ISSN (Print): 2790-2463
Volume 3(1) December 2023
Journal homepage: https://journals.iub.edu.pk/index.php/ijnms

Review

Therapeutic effects of *Digitalis purpurea* on cardiovascular system

Hamza Tahir[a]*, Shaman Uroosh[a], Muhammad Ibrahim Khalil [b]

[a] Department of Eastern Medicine and Surgery, University of Poonch Rawalakot, AJK, Pakistan.
[b] Department of Physiology Neurosciences Li Lab, Dalian Medical University Liaoning China.

Abstract

Cardiac glycosides have been widely utilized in the treatment of congestive heart failure since William Withering first described their use in his research on the efficacy of the leaves of the *Digitalis purpurea* (common foxglove plant) in the late 18th century. Despite being widely used in medical practice for the next 200 years, these classes of remedy' effectiveness and safety are still hotly contested issues. It is also debatable whether the sympatholytic or positive inotropic effects of these drugs are the mechanism most relevant to relieving cardiac failure symptoms in people with systolic ventricular dysfunction, despite the fact that their molecular target for action is the a-subunit of sarcolemma Na+ K+ -ATPase found on most eukaryotic cell membranes. In this article, we go through the clinical and molecular pharmacology of this venerable class of remedy, as well as the symptoms of *Digitalis purpurea* poisoning and how to manage them. The effectiveness of this remedy in treating cardiac failure is also reviewed in considerable depth, with an emphasis on the Digoxin Investigation Group data set. The use of *Digitalis purpurea* preparations will inevitably decline with the maturation of newer pharmacotherapies, even though, in our opinion, the data overall support their continued use for the care of cardiac failure symptoms in sufferers already taking modern multidrug therapy for this disease.

Correspondence:
hamzakhan000100@gmail.com

Keywords: Drugs, therapeutic effect, *Digitalis purpurea*, cardiac failure, pharmacology

Citation: Hamza Tahir, Shaman Uroosh, Muhammad Ibrahim Khalil. Therapeutic effects of *Digitalis purpurea* on cardiovascular system. IJNMS. 2023; 3(1): 33-40

Introduction: Northwestern Africa, Western Asia, and Europe are the natural habitats of Digitalis. The species-specific colors of the tubular blooms, which are produced on a tall spike, range from purple to pink, white, and yellow. The term "finger" in science parlance.

• Domain	Eukaryotes
• Kingdom	Plantae
• Genus	Digitalis
• Order	Lamiales
• Family	Plantaginaceae
• English name	Digitalis
• Scientific name	Digitalis purpurea
• Common name	Foxglove
• Urdu name	Datura

Medicinal uses: Since William Withering defined their finding in his famous book on the effectiveness of the leaves of the *Digitalis purpurea* in 1785, cardiac glycosides have been a key component of the care of congestive cardiac failure [1]. However, there has been debate regarding whether the hazards of digitalis preparations outweigh their advantages during the entirety of this century, particularly in sufferers with cardiac failure in sinus rhythm. An overview of the fundamental and clinical pharmacology of cardiac glycosides is provided at the outset of this study, and recent clinical trials that looked at the use of digoxin in people with moderate to severe congestive cardiac failure are then examined. Any steroid or steroid glycoside substance that has the distinctively favourable inotropic and electrophysiological effects on the cardiac is referred to as "Digitalis" or "cardiac glycosides" throughout the text. Due to the ease with which methods for determining its levels in serum are readily available, the versatility of its administration routes, and its intermediate duration of action, digoxin is by far the most often recommended of these remedy in the 1990s. Standard texts give substantial consideration to sources of cardiac glycosides, their chemistry, and correlations between structure and action [2, 3].

***Digitalis purpurea* toxicity:** Several lethal physiological and chemically linked cardiac and steroidal glycosides may be present in the *Digitalis purpurea* plant, depending on the species. As a result, the plants known as Digitalis have acquired additional, darker monikers, such as witch's gloves and dead man's bells. Toxins can be ingested or absorbed through the skin [4]. An excess of Digitalis can result in Digitalis intoxication, sometimes referred to as digitalism, which can include neurological, cardiac, and gastrointestinal side effects. The former includes loss of appetite, nausea, vomiting, and diarrhea; the latter include bradycardia and tachycardia, either of which can cause syncope if severe enough; and the latter include fatigue, delirium, and infrequently xanthopsia (jaundiced or yellow vision) [4,5,6]. Additional oculotoxic effects of Digitalis include the appearance of blurred outlines (often known as "halos") and generalized blurriness in vision [7]. Dilated pupils, drooling, weakness, collapse, convulsions, and even death are further symptoms cited. Via a direct impact on the vagal nucleus, Digitalis poisoning can result in indirect suppression of the atrioventricular node. Bradycardia, or a lowered heart rate, or, in extreme cases, heart block, are the outcomes of this. Depending on the dosage, the state of the patient's heart, and the blood's current chemistry, cardiac glycosides directly cause heart muscle cells to contract more forcefully and frequently, which tends to cause tachycardia (an elevated heart rate) (specifically any of: low potassium, high calcium, and low magnesium) [8]. While electrical cardioversion (to "shock" the heart) can exacerbate or prolong ventricular fibrillation in Digitalis poisoning, it is typically not recommended in these cases [9,10]. Furthermore, lidocaine is more frequently utilized as the second-choice medication since amiodarone, the traditional treatment of choice for ventricular fibrillation in an emergency situation [11], can exacerbate the dysrhythmia brought on by Digitalis. [12] Anti-digoxin antibody fragments are used to treat severe toxicity; discontinuing the drug and using general supportive measures are the treatments for mild toxicity.

Mechanism of Action

Mood of action: Inhibiting sodium-potassium ATPase is how *Digitalis purpurea* functions. As a result, there is a decrease in the concentration gradient across the cell membrane and an increase in the intracellular concentration of sodium ions. Because of this rise in intracellular sodium, the Na/Ca exchange experiences a potential reversal, where in it moves from pumping calcium out of the cell in return for pumping sodium into the cell to the opposite situation. Cardiac contractility is enhanced as a result of an increase in the concentration of cytoplasmic calcium [13]. The sarcoplasmic reticulum, an intracellular organelle that accumulates calcium, is the source of the cytoplasmic calcium needed for heart contractions in a healthy organism. The sarcoplasmic reticula of new born humans, certain animals, and those suffering from chronic heart failure are not completely established and functional; thus, they depend on the Na/Ca exchanger to supply most or all of the cytoplasmic calcium needed for cardiac contraction. In order for this to happen, cytoplasmic sodium has to be more concentrated than usual in order to promote a possible reversal. This happens naturally in new born humans and certain animals, mostly as a result of an increased heart rate; in patients suffering from chronic heart failure, it happens as a result of taking Digitalis. Increased contractility leads to an increase in stroke volume. In the end, *Digitalis purpurea* raises cardiac output (heart rate time's stroke volume). This process explains why this medication is as well-liked as a therapy for congestive heart failure, a condition marked by poor cardiac output. Additionally, Digitalis slows the ventricular rhythm during atrial fibrillation by acting as a vagal agent on the parasympathetic nervous system (unless there is an accessory channel, in which case it might paradoxically raise the heart rate) [14]. Due to its reliance on vagal action, Digitalis is ineffective during exercise and in patients with significant sympathetic nervous system drive, such as those who are critically ill [15,16].

Positive Inotropic Effect: It was evident that *Digitalis purpurae* preparations had a positive inotropic effect on the intact ventricle, increasing the rate at which intra-cavity pressure rose during isovolumic systole at constant cardiac rate and aortic pressure, which could be seen in both healthy and failing cardiac muscle Cardiac glycoside injection shifted the intact cardinal's ventricular function (Frank-Starling) curve higher and to the left, increasing the

amount of stroke effort produced at a given filling pressure. Without any signs of desensitization or tachyphylaxis, these effects seem to last for weeks to months after in vivo Digitalis injection. Activator Ca+ is more readily available in cardiac cells when digitalis chemicals are present, and it is now generally accepted that this rise in intracellular Ca+ activity is sufficient to account for both the inotropic and arrhythmogenic actions of these medicines [16, 17].

The intrinsic membrane protein Na+, K+-ATPase is a powerful and highly selective target of all cardio active steroids. This enzyme is part of the cellular "sodium pump," which combines the hydrolysis of a high-energy ATP phosphate with membrane ion translocation. Indeed, Jens Skou's discovery of the enzyme activity he named the Na+, K+-ATPase in the 1960s and characterized in the enormous neurons of mussels won him the 1997 Nobel Prize in Chemistry. [4] The Na+, K+, and ATP binding sites of the intact enzyme are located in the a-subunit of the heterodimer enzyme, which has been highly conserved in eukaryotes for the establishment and maintenance of Tran's membrane Na+ and K+ gradients [17].

The fact that the extra cytoplasmic face of the a-subunit has a binding site for the cardiac glycosides is another long-standing feature of Na+, K+ -ATPase that sets it apart from other P-type ATPase. Because the amino acid sequence and conformation that make up the "Digitalis binding site" on Na+, K+ -ATPase are so highly conserved across many phyla and millennia, the highly selective action of the cardiac glycosides to bind to this site has given rise to much speculation about the potential existence of endogenous ligands. Although fascinating information is available [6, 9], there isn't yet concrete evidence that any "endogenous digitalis" actually exists and has a specific biological role in controlling Na+, K+ -ATPase activity.

The mechanism of Digitalis-induced positive inotropic is known to include an altered balance between intracellular Na+ and Ca+, and compelling direct evidence has now been acquired to support rises in intracellular Na concentration or activity induced by cardiac glycosides. When Digitalis reduces outward Na+ pumping, Tran's membrane Na+ influx that occurs with every action potential results in rise in intracellular Na+ concentration that rises intracellular Ca+ stores either through improved Ca+ entry, decreased Ca+ efflux, or both. These effects are thought to be mediated by Na+, -Ca+ exchange. It's interesting to note that recent research suggests that the immediate positively inotropic effect of cardiac glycosides is achieved with remarkable energy transfer efficiency and little oxygen wasting, whether it's measured in the intact cardiac of a conscious dog model or in isometrically contracting papillary muscle strips [18]. Last but not least, Santana and colleagues [19] have shown that physiologically relevant (i.e., Nano molar) concentrations of cardiac glycosides can change the ion selectivity of voltage-sensitive Na+ channels in sarcolemma and T-tubular membranes, allowing Ca+ entry by a mechanism they have dubbed "slip-mode conductance." Further research will be needed to determine how this result relates to the way that these remedy work.

Effects on electrophysiology: Similar to how these remedy have favorable inotropic effects, it is thought that Digitalis preparations have a large impact on cardiac rhythm because they block the salt pump. However, there are differences in the sensitivity of the cells throughout the cardiac to Digitalis, and it is now known that both direct and neutrally mediated effects can occur. In fact, at therapeutic digoxin levels, these remedy enhance maximal diastolic potential and decrease automaticity, effects that are inhibited by atropine, although higher toxic concentrations reverse the effects.

Similar to this, the toxic arrhythmogenic effects of cardiac glycosides result from a mix of direct effects on the cardiac and rises in autonomic activity that is mediated by brain processes. The concept that intracellular "Ca+ overload" contributes to the observed arrhythmogenic effects has been supported by the observation that both systolic and diastolic [Ca+] rise during Digitalis-induced arrhythmias, rises that were initially inferred from changes in tension. After depolarization and after contractions originate from spontaneous cycles of Ca+ release and reuptake that follow. The Ca+-activated transient inward current, which causes the after depolarization, is assumed to represent the macroscopic expression of Ca+-activated nonspecific cation channels along with the Na+-Ca+ exchange current.

Cardiac Glycosides' Neutrally Mediated Actions: It's critical to comprehend how Digitalis glycosides affect aberrant autonomic nervous system activity, particularly altered bar reflex activity, which is a hallmark of progressive cardiac failure. Observed by Mason and Braun Wald [20] in normal human volunteers 30 years ago, intravenous ouabain raised mean arterial pressure, forearm vascular resistance, and venous tone, perhaps in part due to direct but brief effects on vascular smooth muscle. In contrast, individuals with cardiac failure responded with a decrease in cardiac rate and other symptoms associated with raised bar reflex responsiveness, as shown in the figure. More recently, Ferguson et al. [21] shown that deslanoside, a rapidly acting cardiac glycoside, raised forearm blood flow and cardiac index and decreased cardiac rate concurrently with a marked decrease in skeletal muscle sympathetic nerve activity measured as an indicator of centrally mediated sympathetic nervous system activity. These effects occurred in sufferers with moderate to severe cardiac failure. Dobutamine, a sympathomimetic medication that similarly boosted cardiac output, on the other hand, had no impact on the activity of the muscular sympathetic nerve in these individuals. Based on these and other data [22] there may be a significant mechanism underlying the effectiveness of cardiac glycosides in the care of individuals with cardiac failure.

Dosage of digoxin: In most individuals with heart failure and normal sinus rhythm, peak digoxin body storage of 8 to 12 mcg/kg often offers a therapeutic benefit with little risk of harm. It is recommended to provide the loading dosage in many portions, with the first dose being roughly half of the total. At intervals of six to eight hours, further portions of the entire dose may be administered. Prior to administering any next dosage, the patient's clinical reaction should be carefully evaluated. In the event that the patient's reaction requires a modification from the estimated loading dose of digoxin, the maintenance dosage should be computed using the actual dosage administered.

Digoxin is the most commonly given cardiac glycoside preparation, despite the fact that there are still a number of other options available, and its pharmacology will be covered in length. For a summary of the pharmacology of other cardiac glycosides that are still in use in clinical settings, the reader is directed to thorough textbooks. [23] With an elimination half-life of 37 to 48 hours in individuals with normal renal function, digoxin is excreted exponentially, causing the body to lose around one-third of its daily storage. Digoxin excretion in the kidneys is inversely correlated with glomerular filtration rate and, consequently, with creatinine clearance. A steady state is attained with daily maintenance care when daily losses and daily intake are equal. When daily maintenance medication is started without a loading dose for sufferers who have never received digoxin, participants with normal renal function reach steady-state plateau concentrations after 4 to 5 half-lives, or 7 to 10 days. The period of time before a steady state is established on a daily maintenance dosage would be correspondingly lengthened if the drug's elimination rate was prolonged. Calculating a sufferer's maintenance dose should take into account their predicted lean body mass. Additionally, new research reveals that chronic renal failure reduces the steady-state volume of distribution of digoxin; therefore, sufferers who have this condition should get lower loading and maintenance doses of the drug [24,25]. Digoxin dosages are significantly greater in neonates and babies than in adults, leading to considerably higher blood digoxin concentrations, which are often tolerated well. Digoxin does pass through the placenta, and levels in the fetal umbilical cord's venous blood are comparable to those in the mother's. Digoxin use during pregnancy or breastfeeding is not against the rules.

Except in the case of specific supraventricular arrhythmias where other remedy beneficial in treating these arrhythmias are prohibited or have failed to work, sufferers are often not treated with a loading dosage of digoxin. This is because cardiac glycosides have a limited therapeutic "window," and it is sometimes challenging to determine an exact loading dose of digoxin that would also reduce the risk of toxicity. The individuals who might most benefit from the inclusion of a cardiac glycoside are frequently those who are most likely to experience the harmful side effects of these remedy (see below in figure 1A, 1B). There is disagreement regarding the ideal therapeutic range for digoxin since the cardiac glycosides' mode of action, which is crucial to their positive benefits in cardiac failure sufferers, is yet unknown. Based on the clinical trial data examined below, our analysis of the current consensus would place that range between 0.5 and 1.5 mg/mL.

Peripheral vascular resistance and cardiac glycosides in cardiac failure A, a 10-minute intravenous infusion of ouabain, a hydrophilic, rapidly acting cardiac glycoside, into healthy subjects raised mean arterial pressure as well as forearm vascular resistance and venous tone, as shown in this illustrative example. This finding was reported in a series of groundbreaking studies by Mason and Braun Wald [26]. However, after receiving intravenous ouabain, sufferers with advanced cardiac failure saw a decrease in forearm vascular resistance and venous tone, as seen in Figure B. The rapid, opposite hemodynamic effect is thought to be caused by a decrease in sympathetic nervous system activity, which is mediated by raised sensitivity of the bar reflex response, in cardiac failure sufferers as opposed to the response in normal subjects, which is likely partly caused by a direct effect of cardiac glycosides on peripheral vascular tone. Adapted from Mason and Braun Wald [27] with permission, a sufferer's fate is frequently uncertain.

Adverse drug reactions: The pharmacokinetics of Digitalis preparations may be directly altered by concurrent medication administration, or their cardiac effect may be indirectly altered via pharmacodynamics interactions. Digoxin's volume of distribution is reduced by quinidine, which also lessens its renal and non-renal elimination. Recent research suggests that quinidine, which has a high affinity for P-glycoprotein, an ATP-dependent efflux pump that is encoded by the mdr1a gene, inhibits digoxin transport across epithelial cell membranes, specifically in the kidney [28]. Given that amiodarone care raises the steady-state concentration of digoxin, maintenance dosages of digoxin should be cut by 50%. It will be important to closely monitor newly released remedy for interactions with cardiac glycosides. Concomitantly administered diuretic remedy is an example of pharmacodynamics interactions. These remedy may rise the risk of Digitalis toxicity by decreasing glomerular filtration rate due to volume depletion and by causing a number of electrolyte disturbances, such as hypokalemia, hypomagnesaemia, and hypercalcemia. Additionally, the concomitant use of various antiarrhythmic remedy may raise the risk of arrhythmic events, a result that can often vary from sufferer to sufferer.

***Digitalis purpurea* Toxicology**

Electrophysiological Abnormalities: Premature ventricular contractions are one of several ECG signs of digoxin poisoning, although they are typically too generic to be diagnosed. Junctional pacemakers may start to discharge more often at greater dosages, causing a non-paroxysmal AV Junctional tachycardia. The paradoxical regularization of the ventricular rate despite continuous atrial fibrillation is recognized clinically in this situation. Tachycardia’s that result from raised atrial automaticity is frequent supraventricular arrhythmias connected to digitalis poisoning. Even in sufferers whose serum levels are within the acceptable therapeutic range, the combination of enhanced automaticity and impaired conduction (e.g., AV block accompanied by an accelerated Junctional pacemaker) is highly suggestive of toxicity. This is true even though there is no single ECG abnormality that is pathognomonic of digitalis excess.

Hypokalemia rises the improved automaticity of cardiac tissue in response to hazardous amounts of cardiac glycosides in experimental animals, but hyperkalemia inhibits the emergence of delayed after depolarization that might approach threshold. However, hyperkalemia has the potential to exacerbate the conduction delays brought on by Digitalis, particularly in the AV node. Additionally, and perhaps synergistically with the effects of Digitalis, higher blood CA levels improve ventricular automaticity. When intravenous calcium is administered parentally to individuals who have had digitalis, fatal ventricular arrhythmias may result.

Therapy for *Digitalis purpurea* Toxicology:

Early identification that cardiac arrhythmia is attributable to *Digitalis purpurae* intoxication is essential for effective therapy. The more frequent symptoms, such as sporadic ectopic beats, pronounced first-degree AV block, or atrial fibrillation with a sluggish ventricular response, only call for brief medication cessation and ECG monitoring. Digitalis intoxication-related ventricular tachycardia needs prompt aggressive care. Atropine is frequently successful in treating sinus bradycardia, Sino atrial arrest, and second- or third-degree AV block, although pacing may be necessary in some cases. Even when the serum potassium level is within the "normal" range, the administration of potassium salts is advised for ectopic ventricular arrhythmias. Digoxin has a wide volume of distribution, making hemodialysis inefficient for treating digoxin toxicity. Although a number of antiarrhythmic remedy have been used to treat Digitalis-induced ventricular arrhythmias, digoxin-specific antibody fragment injection is now the first-line therapy for life-threatening Digitalis toxicity. The practitioner has a method for quickly and selectively reversing Digitalis toxicity with low danger of side effects thanks to the widespread availability of Fab segments of high-affinity, polyclonal, digoxin-specific antibodies. [29] ant digoxin Fab fragments have now been administered to a number of individuals without any negative side effects.

Supraventricular Tachycardia and Digoxin:

As mentioned above, the main way that cardiac glycosides reduce sympathetic nervous system activity, especially in sufferers with cardiac failure, and rise parasympathetic nervous system activity is to delay the ventricular response in supraventricular tachycardia. Digoxin's limited effectiveness in treating paroxysmal atrial fibrillation has been replaced during the past 20 years by the development of newer, more effective, and safer remedy. The only individuals with supraventricular tachycardia for whom cardiac glycosides are still an effective supplementary therapy are those who have symptomatic ventricular systolic dysfunction and atrial fibrillation (acute and chronic). In this population, digoxin is often only enough for ventricular rate regulation in individuals with moderately well-compensated cardiac failure at rest.

Safety and effectiveness in cardiac failure; clinical trials

Relevance of Serum Digoxin Levels: Digoxin's sympatholytic effects may manifest at blood drug concentrations lower than those required to produce a conventional positively inotropic effect, according to recent evidence from a few clinical trials, which are detailed below. According to Gheorghiade et al. [30] increasing the dose from a mean of 0.2 to 0.39 mg/d (corresponding to a rise in serum levels from 0.67 to 1.22 mg/mL) raised ejection fraction but had no further effect on exercise tolerance or a decline in venous norepinephrine levels. This finding was corroborated by at least a few more small clinical trials [31].

The fact that sufferers with high digoxin levels (.1.1 mg/mL) had a higher mortality rate in a clinical trial intended to examine the impact of milrinone on survival in sufferers with cardiac failure (the Prospective Randomized Milrinone Survival Evaluation [PROMISE]), an effect that was independent of ejection fraction, may be due to the possibility that digoxin may exhibit multiple mechanisms of action over the range of serum concentrations attained clinically [32]. Therefore, wise use of digitalis necessitates early detection of possible toxicity as well as awareness of concurrent drugs or disease conditions that may impact digoxin pharmacokinetics, all of which are still necessary for a safe and effective dosage of this family of therapies [33].

Small clinical trials in sufferers of cardiac failure

Digoxin has been shown to offer a wide range of advantages in both short- and long-term controlled and uncontrolled clinical studies [34]. In 2 prospective, multicenter, placebo-controlled trials, PROVED (Prospective Randomized Study of Ventricular Failure and Efficacy of Digoxin) [35] and RADIANCE (Randomized Assessment of Digoxin on Inhibitors of Angiotensin-Converting Enzyme) [26], sufferers with stable mild to moderate cardiac failure and systolic ventricular dysfunction. The target blood digoxin levels in both trials during the first run-in phase ranged from 0.9 to 2.0 mg/mL, and in RADIANCE, sufferers in the study also received concomitant medication with an angiotensin converting enzymes inhibitor. All of the sufferers evaluated were in sinus rhythm. 40% of sufferers in PROVED and 28% of sufferers in RADIANCE who received placebo reported a significant worsening of cardiac failure symptoms compared to 20% and 6%, respectively, of sufferers who continued to receive active digoxin therapy. This difference was seen when sufferers were randomly assigned to continue active digoxin therapy or withdraw from active therapy and receive a matching placebo. A significant therapeutic benefit was this absolute risk reduction of 20% in digoxin-treated individuals. The survival of sufferers with cardiac failure, an end point for which effectiveness had already been shown for the use of certain vasodilators in this condition, was the only outcome for which neither of these studies had the statistical power to detect an impact of digoxin medication.

Trial of the *Digitalis purpurea* Investigation Group:

The major multicenter Digitalis Investigation Group experiment, which consisted of two trials conducted in a total of 302 centers in the United States and Canada, was intended to settle a number of ongoing disputes over the function of digoxin [35,37]. Sufferers had to be in sinus rhythm, have a confirmed left ventricular ejection fraction of 0.45, and have cardiac failure as established by predetermined signs, symptoms, or radiological criteria in order to participate in the "main" trial. Since prior or current digoxin medication was acceptable, the digitalis investigation group experiment effectively doubled as a digoxin withdrawal study.

ACE inhibitors were not required but were "strongly encouraged" to be used; additional remedy might be added at the investigator's discretion; and follow-up was planned for at four weeks, four months, and then every following four months. All-cause mortality was the major end target, while supplementary end points were cardiovascular causes of death, cardiac failure-related deaths, and cardiac failure-related hospitalizations. There were no changes in baseline characteristics between the active-drug and placebo groups among the 6700 sufferers who participated in this primary study, including demographics, the etiology of cardiac failure, ejection fraction, and the dose of digoxin

administered, or the usage of angiotensin converting enzyme inhibitors, nitrates, or diuretics [38].

There were no changes in cardiovascular or all-cause mortality after a mean follow-up of 36 months (range, 28 to 58 months). With a relative risk of 0.89 (96% CI, 0.78 to 1.02), there was a tendency for the mortality rate from cardiac failure to decline. Digoxin sufferers had a relative risk of 0.73 (96% CI, 0.67 to 0.78) for hospitalization for cardiac failure, which is the crucial distinction between the digoxin and placebo groups (Table 1). When paired with the mortality end points, this impact remained statistically significant due to its size. Sufferers with ejection fractions of 26% and those with more severe symptoms saw a larger relative risk decrease. The findings from PROVED [32] and RADIANCE are supported by the observation that the cardiac failure survival and hospitalization curves appear to diverge early after randomization, particularly in the sufferer subgroup from which digoxin was withheld [39].

More sufferers receiving placebo than digoxin (23.0% versus 15.2%) received open-label digoxin. At one month, 89% of the sufferers in the subgroup with reported digoxin levels were within the recommended therapeutic range of 0.6 to 2.1 mg/ml. Overall, the number of cardiovascular hospitalizations (1695, or 48.9%, against 1860, or 55.4%) was almost 11% lower, and there were also fewer hospitalizations for every sufferer receiving digoxin. Additionally, both individuals taking digoxin at the time of randomization and those not previously receiving the medication saw a similar reduction in the risk of passing away or needing hospitalization due to worsening cardiac failure [40-41].

Despite these positive findings, there was a rise in fatalities from other cardiac conditions in the digoxin-receiving group. In addition to deaths from atherosclerotic coronary disease, low-output states, and cardiac surgery, this group also includes deaths thought to be the result of tachyarrhythmia's or Brady arrhythmias without increasing cardiac failure. Out-of-hospital mortality thought to be caused by an arrhythmia was not a predetermined end goal, and no data from the study for this distinct group have been released [42].

Therefore, despite the extensive data collection that results from the digoxin investigation group trial, we are only partially able to settle all current digoxin-related disputes using the digoxin investigation group trial data set. Unanswered is the question of the "ideal" serum digoxin level, which would be the most effective and least harmful. Additionally, a subgroup of 582 sufferers from the primary and secondary studies of the digoxin investigation group trial (ejection fractions of less than 0.46 and greater than 0.46, respectively) completed 7-minute corridor walks and a variety of quality-of-life questionnaires at enrolment as well as at 2, 5, and 11 months. Between the digoxin and placebo groups, no statistically significant changes were found, although it's conceivable that this sub-study lacked the statistical power to identify differences among the most symptomatic sufferers. Finally, the development of remedy that directly suppress the sympathetic nervous system's activity in cardiac failure, particularly the b-adrenergic antagonists, further complicates any assessment of the likelihood that digoxin will remain a cornerstone of standard cardiac failure therapy [43, 44]. In the post-digoxin investigation group trial age, it seems doubtful that another study will be conducted to address the unresolved clinical concerns. The time and money needed to register sufferers in a non-industry-sponsored trial of a sufficiently potent generic medicine are prohibitive. Furthermore, a larger sufferer population will be needed to demonstrate a survival benefit as standard pharmacological therapy for cardiac failure advances. The assumption is that the argument over digitalis and its use will wane in intensity in the context of the development of newer medicines that emphasize survival as the key outcome, even without a clear proclamation of triumph by supporters or opponents.

Conclusion:

At last, the development of remedy which directly suppress the fight on flight nervous system's activity among cardiac arrest, especially b-adrenergic opponent, further complicates any evaluation of probability that digoxin would go on cornerstone of quality cardiac arrest treatment. In the post-digoxin investigation group trial age, it seems doubtful that another study will be conducted to address the unresolved clinical concerns. The time and money needed to register sufferers in non-industry promote test of sufficiently potent generic medicine are prohibitive. Furthermore, a larger sufferer population will be needed to demonstrate a survival benefit as standard pharmacological therapy for cardiac failure advances. The assumption is that the argument over digitalis and its use will wane in intensity among context of development of latest medicines which emphasize life span as key results, even without a clear proclamation of triumph by supporters or opponents.

Conflict of Interest:

Authors declare that there is no conflict of interest among authors.

References

1. Guadalajara-Boo JF. Digitalis Medication in Treatment of Heart Failure. Chinese Medicine. 2024 Jan 11;15(01):1-3.
2. Baharvand Ahmadi B, Khajoei Nejad F, Papi S, Eftekhari Z. Phytotherapy for heart tonic: An ethnobotanical study in Dehloran City, Ilam Province, Western Iran. Caspian Journal of Environmental Sciences. 2023 Jan 31:1-5.
3. Blaustein MP, Gottlieb SS, Hamlyn JM, Leenen FH. Whither digitalis? What we can still learn from cardiotonic steroids about heart failure and hypertension. American Journal of Physiology-Heart and Circulatory Physiology. 2022 Dec 1;323(6):H1281-95.
4. Parikh RR, Patel KR, Pergolizzi Jr JV, Breve F, Magnusson P, Patel K, Pergolizzi Jr J. Effects of digoxin in heart failure (HF) with reduced ejection fraction (EF). Cureus. 2022 Mar 2;14(3).
5. Parikh RR, Patel KR, Pergolizzi Jr JV, Breve F, Magnusson P, Patel K, Pergolizzi Jr J. Effects of digoxin in heart failure (HF) with reduced ejection fraction (EF). Cureus. 2022 Mar 2;14(3).
6. Hashemi-Shahri SH, Aghajanloo A, Ghavami V, Arasteh O, Mohammadpour AH, Reiner Ž, Sahebkar A. Digoxin and outcomes in patients with heart failure and preserved ejection fraction (HFpEF) patients: a systematic review and meta-analysis. Current Drug Targets. 2023 Feb 1;24(2):191-200.
7. Pandya L, Brown DL. The association of digoxin with mortality in ischemic heart failure: a secondary analysis of the STICH trial. European Heart Journal. 2020 Nov;41(Supplement_2):ehaa946-0882.
8. Zhou J, Cao J, Jin X, Zhou J, Chen Z, Xu D, Yang X, Dong W, Li L, Fan Y, Chen L. Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction. ESC Heart Failure. 2020 Feb;7(1):139-47.
9. van Veldhuisen DJ, Rienstra M, van der Meer P. Value of digoxin in patients with heart failure: new pieces to the puzzle. European Journal of Heart Failure. 2018 Jul;20(7):1146-7.
10. Aguirre Dávila L, Weber K, Bavendiek U, Bauersachs J, Wittes J, Yusuf S, Koch A. Digoxin–mortality: randomized vs. observational

comparison in the DIG trial. European heart journal. 2019 Oct 21;40(40):3336-41.
11. Pal V, Pant M. Digitalis purpurea (Foxglove Plant). InExploring Poisonous Plants 2023 Mar 14 (pp. 241-254). CRC Press.
12. Jadhav D, Borse DS, Baviskar CG, Hatkar AK, Kawade RM. To prepare suspension of Digitalis for congestive heart failures. International Journal of Pharmaceutical Sciences. 2023 Dec 23;1(12):1-.
13. Baharvand Ahmadi B, Khajoei Nejad F, Papi S, Eftekhari Z. Phytotherapy for heart tonic: An ethnobotanical study in Dehloran City, Ilam Province, Western Iran. Caspian Journal of Environmental Sciences. 2023 Jan 31:1-5.
14. Carroll E, Ravi Gopal B, Raghavan I, Mukherjee M, Wang ZQ. A cytochrome P450 CYP87A4 imparts sterol side-chain cleavage in digoxin biosynthesis. Nature communications. 2023 Jul 8;14(1):4042.
15. Chmielewski J, Pietrus M, Wartęga M. Endogenous digitalis-like factors as a key molecule in the pathophysiology of pregnancy-induced hypertension and a potential therapeutic target in preeclampsia. International Journal of Molecular Sciences. 2023 Aug 13;24(16):12743.
16. MacLeod KT. Changes in cellular Ca2+ and Na+ regulation during the progression towards heart failure. The Journal of Physiology. 2023 Mar;601(5):905-21.
17. Halliday BP, Lüscher TF, Voors AA, Moura B, Lund L, Lam CS, de Boer RA, Pieske B, Borlaug BA. Clinical phenotypes of chronic heart failure. The ESC Textbook of Heart Failure. 2023 Nov 14:269..
18. Jadhav D, Borse DS, Baviskar CG, Hatkar AK, Kawade RM. To prepare suspension of Digitalis for congestive heart failures. International Journal of Pharmaceutical Sciences. 2023 Dec 23;1(12):1-.
19. Whayne Jr TF. Clinical use of digitalis: a state of the art review. American journal of cardiovascular drugs. 2018 Dec;18(6):427-40..
20. Gheorghiade M, Hall VB, Jacobsen G, Alam M, Rosman H, Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in sufferers with chronic cardiac failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation. 2020 22:1801–1807.
21. Tuxtashovich MS, Omonovich JL, Abduqaxxor o‘g‘li SU, Ikromjon o‘g IT. Effect and use of cardiac glycosides on the body. Multidisciplinary Journal of Science and Technology. 2024 Jan 21;4(1):163-6.
22. Koca HB, Oncu S, Becit-Kizilkaya M, Gokaslan S. Evaluation of therapeutic and toxic levels of serum digoxin concentration: a cross-sectional study from a tertiary hospital. European Review for Medical and Pharmacological Sciences. 2024 Feb 1;28(3):1036-43.
23. Singhai H, Rathee S, Jain SK, Patil UK. The Potential of Natural Products in the Management of Cardiovascular Disease. Current Pharmaceutical Design. 2024 Mar 1;30(8):624-38.
24. Fairuz S, Ang CW, Mraiche F, Goh JK. Current Targets and Future Directions of Positive Inotropes for Heart Failure. Current Medicinal Chemistry. 2024.
Kanuri SH, Sirrkay PJ. Adjuvants in COVID-19 vaccines: innocent bystanders or culpable abettors for stirring up COVID-heart syndrome. Therapeutic Advances in Vaccines and Immunotherapy. 2024 Feb;12:25151355241228439.
26. Tuxtashovich MS, Omonovich JL, Abduqaxxor o‘g‘li SU, Ikromjon o‘g IT. Effect and use of cardiac glycosides on the body. Multidisciplinary Journal of Science and Technology. 2024 Jan 21;4(1):163-6.
27. Tokhirovich AA, Maksudjanovna MG. Phytopharmacokinetics of Medicinal Plants and Drug Preparations Affecting Cardiovascular Diseases. Web of Semantics: Journal of Interdisciplinary Science. 2024 Feb 22;2(2):10-2.
28. Petrovna PG, Andreevna KL, Borisovna PS. UDC 616.12-008.46-085: 612.396 MODERN APPROACH TO THE TREATMENT OF GLYCOSIDE INTOXICATION. InThe 8 th International scientific and practical conference “Scientific research in the modern world”(June 1-3, 2023) Perfect Publishing, Toronto, Canada. 2023. 639 p. 2023 Jun 1 (p. 40).
29. Koca HB, Oncu S, Becit-Kizilkaya M, Gokaslan S. Evaluation of therapeutic and toxic levels of serum digoxin concentration: a cross-sectional study from a tertiary hospital. European Review for Medical and Pharmacological Sciences. 2024 Feb 1;28(3):1036-43.
30. Jiratham‐Opas J, Kanjanavanit R, Wongcharoen W, Punyawudho B, Arunmanakul P, Amaritakomol A, Topaiboon P, Gunaparn S, Phrommintikul A. Can available mathematical models predict serum digoxin levels in Thai patients?. Journal of Clinical Pharmacy and Therapeutics. 2018 Jun;43(3):377-84.
31. Becit-Kizilkaya M, Gokaslan S. Evaluation of therapeutic and toxic levels of serum digoxin concentration: a cross-sectional study from a tertiary hospital. European Review for Medical and Pharmacological Sciences. 2024 Feb 1;28(3):1036-43.
32. Salama M, Ezzat SM, Salem M. Natural products for the management of cardiovascular diseases.2020
33. Pant M. Digitalis purpurea (Foxglove Plant). InExploring Poisonous Plants 2023 Mar 14 (pp. 241-254). CRC Press..
34. Borse DS, Baviskar CG, Hatkar AK, Kawade RM. To prepare suspension of Digitalis for congestive heart failures. International Journal of Pharmaceutical Sciences. 2023 Dec 23;1(12):1-.
35. Khajoei Nejad F, Papi S, Eftekhari Z. Phytotherapy for heart tonic: An ethnobotanical study in Dehloran City, Ilam Province, Western Iran. Caspian Journal of Environmental Sciences. 2023 Jan 31:1-5.
36. Ravi Gopal B, Raghavan I, Mukherjee M, Wang ZQ. A cytochrome P450 CYP87A4 imparts sterol side-chain cleavage in digoxin biosynthesis. Nature communications. 2023 Jul 8;14(1):4042..
37. Singhai H, Rathee S, Jain SK, Patil UK. The Potential of Natural Products in the Management of Cardiovascular Disease. Current Pharmaceutical Design. 2024 Mar 1;30(8):624-38.
38. Tuxtashovich MS, Omonovich JL, Abduqaxxor o‘g‘li SU, Ikromjon o‘g IT. Effect and use of cardiac glycosides on the body. Multidisciplinary Journal of Science and Technology. 2024 Jan 21;4(1):163-6.
39. Menezes Migliani de Castro G, da Silva Fontes Y, Grego Alves SL, Oliveira Barbosa LA, Villar JA, Galina Filho A, Seabra SH, Silva Barreto AL, Tessis AC, Nico D, Ferreira-Pereira A. In vitro and in vivo effects of digoxin derivatives on promastigotes and amastigotes of Leishmania infantum. Journal of Taibah University for Science. 2024 Dec 31;18(1):2289240.
40. Morsy N. Effect of Uzarin Isolated from Calotropis procera on Blood Electrolytes and Cardiac Related Enzymes. Ind. J. Pharm. Edu. Res. 2024;58(1):204-11.
41. Zaczkiewicz M, Zimmermann O, Torzewski J. A short review on CRP synthesis inhibition in cardiovascular disease. Frontiers in Drug Discovery. 2024 Mar 4;4:1338535.
42. Guadalajara-Boo JF. Digitalis Medication in Treatment of Heart Failure. Chinese Medicine. 2024 Jan 11;15(01):1-3.
43. Tuxtashovich MS, Omonovich JL, Abduqaxxor o‘g‘li SU, Ikromjon o‘g IT. Effect and use of cardiac glycosides on the body. Multidisciplinary Journal of Science and Technology. 2024 Jan 21;4(1):163-6.
44. Rathee S, Jain SK, Patil UK. The Potential of Natural Products in the Management of Cardiovascular Disease. Current Pharmaceutical Design. 2024 Mar 1; 30(8):624-38.



Figure 1 (A,B) : clinical trial data examined below, our analysis of the current consensus

Relative Risk Reduction in Hospitalizations With Digoxin Therapy

	Digoxin (n=3397), n (%)	Placebo (n=3403), n (%)	Absolute Difference, %	Relative Risk (95% CI)	P
Reason for hospitalization					
Total cardiovascular	1694 (49.9)	1850 (54.4)	−4.5	0.87 (0.81–0.93)	<0.001
Worsening heart failure	910 (26.8)	1180 (34.7)	−7.9	0.72 (0.66–0.79)	<0.001
Suspected digoxin toxicity	67 (2.0)	31 (0.9)	1.1	2.17 (1.42–3.32)	<0.001
No. of patients hospitalized	2184 (64.3)	2282 (67.1)	−2.8	0.92 (0.87–0.98)	0.006
No. of hospitalizations	6356	6777			

Adapted from the Digitalis Investigation Group.[27]